Aadi Bioscience wins arbitration; panel finds no breach, no damages to EOC

Whitehawk Therapeutics, Inc.

Arbitration panel issued Final Award on Sept 26, 2024, in favor of Aadi Bioscience.
Panel concluded Aadi did not breach the December 2020 EOC License Agreement.
EOC Pharma sought monetary damages; none awarded.
Dispute began in June 2022, centered on alleged failure to provide manufacturing info.
Outcome removes a significant legal overhang for the company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.